GSK
Baar, Switzerland
Site Name: Baar Onyx, GSK House, Munich Posted Date: Feb 1 2023 Details Medical Affairs is a critical bridge between R&D and the commercial organization to ensure that our medicines reach the appropriate patients. GSK has committed to building a new oncology business, with initial focus on selected EU markets. To this end, this is a critical role to ensure hematology/oncology resource and activities are aligned and deployed to business priorities in the EU region. GSK's Oncology portfolio consists of 3 pillars: Gyneco-Oncology with its launched products Zejula and Jemperli Pipeline with several assets in development across several therapeutic areas including lung cancer, head&neck and GI-cancers Hematology is a focus area with Blenrep as key asset in Multiple Myeloma expected to grow potentially to GSK's flagship product based on potential line-extensions once data from additional phase III trials will read out in 2023. With the recent acquisition of Sierra...